Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
enVVeno Medical Corp (HJLI)
|
Add to portfolio |
|
|
|
| Price: |
$6.96
| | Metrics |
| OS: |
9.47
|
M
| |
|
|
| Market cap: |
$65.9
|
M
| |
|
|
|
Net cash:
|
$39
|
M
| |
$4.12
|
per share
|
|
EV:
|
$26.9
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.4 | | 0.0 |
| Revenue growth | | | -100.0% | -83.3% | -55.8% | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.4 | | 0.0 |
| Gross profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | | 0.0 |
| Gross margin | | | | 100.0% | 100.0% | 0.6% | | |
| Selling, general and administrative | 15.0 | 11.2 | 4.9 | 4.9 | 6.5 | 5.5 | | 1.3 |
| Research and development | 9.9 | 5.7 | 4.3 | 2.2 | 1.2 | 0.6 | | |
| EBITA | -24.9 | -16.9 | -9.1 | -7.1 | -7.4 | -6.0 | | -1.3 |
| EBITA margin | | | | -22681.8% | -3979.2% | -1416.7% | | |
| Amortization of intangibles | | | | | 0.1 | 0.1 | | |
| EBIT | -24.9 | -16.9 | -9.1 | -7.1 | -7.5 | -6.1 | | -1.3 |
| EBIT margin | | | | -22681.8% | -4039.2% | -1445.9% | | |
| Pre-tax income | -24.7 | -16.5 | -9.1 | -7.6 | -13.0 | -7.8 | | -1.4 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | 0.2 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | | |
| Earnings from continuing ops | -24.7 | -16.5 | -9.7 | -7.6 | -16.4 | -8.3 | | -1.4 |
| Earnings from discontinued ops | | | | | | | | -0.2 |
| Net income | -24.7 | -16.5 | -9.7 | -7.6 | -16.4 | -8.3 | | -1.6 |
| Net margin | | | | -24406.7% | -8765.8% | -1954.8% | | |
| |
| Diluted EPS | ($2.20) | ($1.90) | ($7.54) | ($12.10) | ($1.75) | ($1.35) | | ($0.23) |
| Shares outstanding (diluted) | 11.2 | 8.7 | 1.3 | 0.6 | 9.4 | 6.1 | | 6.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|